RU2005114491A - Соединения, составы и способы их использования - Google Patents

Соединения, составы и способы их использования Download PDF

Info

Publication number
RU2005114491A
RU2005114491A RU2005114491/04A RU2005114491A RU2005114491A RU 2005114491 A RU2005114491 A RU 2005114491A RU 2005114491/04 A RU2005114491/04 A RU 2005114491/04A RU 2005114491 A RU2005114491 A RU 2005114491A RU 2005114491 A RU2005114491 A RU 2005114491A
Authority
RU
Russia
Prior art keywords
optionally substituted
alkyl
phenyl
hydrogen
substituted
Prior art date
Application number
RU2005114491/04A
Other languages
English (en)
Russian (ru)
Inventor
Ксиангпинг КВИАН (US)
Ксиангпинг Квиан
Густав БЕРДЖИНС (US)
Густав Берджинс
Дэвид Джей Младший МОРГАНС (US)
Дэвид Джей Младший МОРГАНС
Стивен Дэвид НАЙТ (US)
Стивен Дэвид Найт
Дашь нт ДХЭНЭК (US)
Дашьянт ДХЭНЭК
Original Assignee
Цитокинетикс, Инк. (Us)
Цитокинетикс, Инк.
Смитклайн Бихем Корпорейшн (Us)
Смитклайн Бихем Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цитокинетикс, Инк. (Us), Цитокинетикс, Инк., Смитклайн Бихем Корпорейшн (Us), Смитклайн Бихем Корпорейшн filed Critical Цитокинетикс, Инк. (Us)
Publication of RU2005114491A publication Critical patent/RU2005114491A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2005114491/04A 2002-10-11 2003-10-02 Соединения, составы и способы их использования RU2005114491A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41788902P 2002-10-11 2002-10-11
US60/417,889 2002-10-11

Publications (1)

Publication Number Publication Date
RU2005114491A true RU2005114491A (ru) 2006-02-10

Family

ID=32094113

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005114491/04A RU2005114491A (ru) 2002-10-11 2003-10-02 Соединения, составы и способы их использования

Country Status (19)

Country Link
US (1) US7476743B2 (cg-RX-API-DMAC7.html)
EP (1) EP1558588A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006502219A (cg-RX-API-DMAC7.html)
KR (1) KR20050075356A (cg-RX-API-DMAC7.html)
CN (1) CN1726198A (cg-RX-API-DMAC7.html)
AR (1) AR044193A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003282665A1 (cg-RX-API-DMAC7.html)
BR (1) BR0315247A (cg-RX-API-DMAC7.html)
CA (1) CA2501938A1 (cg-RX-API-DMAC7.html)
IL (1) IL167936A0 (cg-RX-API-DMAC7.html)
IS (1) IS7798A (cg-RX-API-DMAC7.html)
MX (1) MXPA05003830A (cg-RX-API-DMAC7.html)
NO (1) NO20052267L (cg-RX-API-DMAC7.html)
NZ (1) NZ539643A (cg-RX-API-DMAC7.html)
PL (1) PL375889A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005114491A (cg-RX-API-DMAC7.html)
TW (1) TW200418818A (cg-RX-API-DMAC7.html)
WO (1) WO2004032840A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200503733B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2522450C2 (ru) * 2008-08-07 2014-07-10 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Соединения, оказывающие возбуждающее действие на рецептор активатора пролиферации пероксисом подтипа б, способ получения и применение указанных соединений

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014909A (es) * 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
CN101027309B (zh) 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
DE102006023337A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
JP5343363B2 (ja) * 2008-01-31 2013-11-13 アイシン精機株式会社 シートクッション調整装置
EP2558450A1 (en) 2010-04-15 2013-02-20 Novartis AG Triazole compounds as ksp inhibitors
WO2012095691A1 (en) * 2011-01-15 2012-07-19 Jubilant Life Sciences Ltd. An improved process for producing aminopyridines
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
AU2014315151A1 (en) 2013-09-06 2016-03-03 Inception 2, Inc. Triazolone compounds and uses thereof
SG11201710639YA (en) * 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
AU2017380871C1 (en) 2016-12-21 2025-05-15 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
WO2023192499A1 (en) * 2022-03-30 2023-10-05 Primefour Therapeutics, Inc. Nucleosides for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793532A (fr) * 1971-12-29 1973-06-29 Upjohn Co Nouvelles 1,2,4-triazol-3-ones et leur preparation
US3748339A (en) 1972-05-05 1973-07-24 Upjohn Co 2-(3-(1-(dimethylamino)alkyl)-1,5-dihydro-5-oxo - 1 - substituted-4h-1,2,4-triazol-4-yl)benzophenone and process
NO773853L (no) 1976-11-17 1978-05-19 Montedison Spa Nye fosforsyreestre avledet fra 1,2,4-triazol med insekticid, nematocid og acaricid virkning, og fremstilling av disse
IT1068010B (it) * 1976-11-17 1985-03-21 Montedison Spa Nuovi esteri fosforici derivati dall' 1-2-4 triazolo ad azione insetticida,nematocida e acaricida e loro preparazione
US4487773A (en) 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US5250558A (en) * 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB9211193D0 (en) * 1992-05-27 1992-07-08 Merck Sharp & Dohme Therapeutic agents
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
WO1997014671A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Cyclopentyl tachykinin receptor antagonists
JP2002234874A (ja) * 2000-09-26 2002-08-23 Tanabe Seiyaku Co Ltd 5−フェニルベンジルアミン誘導体、その製法及びその合成中間体
US6727244B2 (en) * 2000-10-26 2004-04-27 Merck & Co., Inc. Mammalian metabolites of a tachykinin receptor antagonist
IL165624A0 (en) * 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2522450C2 (ru) * 2008-08-07 2014-07-10 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Соединения, оказывающие возбуждающее действие на рецептор активатора пролиферации пероксисом подтипа б, способ получения и применение указанных соединений

Also Published As

Publication number Publication date
IL167936A0 (en) 2009-02-11
NZ539643A (en) 2006-11-30
PL375889A1 (en) 2005-12-12
WO2004032840A2 (en) 2004-04-22
CA2501938A1 (en) 2004-04-22
US7476743B2 (en) 2009-01-13
EP1558588A2 (en) 2005-08-03
JP2006502219A (ja) 2006-01-19
TW200418818A (en) 2004-10-01
AR044193A1 (es) 2005-09-07
NO20052267L (no) 2005-05-31
BR0315247A (pt) 2005-08-30
ZA200503733B (en) 2006-02-22
WO2004032840A3 (en) 2004-10-14
US20060189671A1 (en) 2006-08-24
CN1726198A (zh) 2006-01-25
MXPA05003830A (es) 2005-06-23
EP1558588A4 (en) 2006-11-02
IS7798A (is) 2005-04-11
AU2003282665A1 (en) 2004-05-04
KR20050075356A (ko) 2005-07-20

Similar Documents

Publication Publication Date Title
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
RU2004133325A (ru) Соединения, композиции на их основе и способы их использования
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
JP2005536475A5 (cg-RX-API-DMAC7.html)
JP2006502219A5 (cg-RX-API-DMAC7.html)
DK1682178T3 (da) Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet
DE69939532D1 (de) Gamma-aminobuttersäurederivate enthaltende, feste arzneimittel und verfahren zu ihrer herstellung
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
RU94013439A (ru) Гетероциклические соединения, способ их получения, фармацевтическая композиция и способ лечения
DE60003837D1 (de) Tetrapeptid, das die funktionelle aktivität von neuronen stimuliert, dieses enthaltendes pharmakologisches mittel und seine verwendung
CO5160329A1 (es) Metodo para proveer absorcion incrementada de una amina far- maceuticamente aceptable en la sangre de un humano y composi cion que comprende una amina farmaceuticamente un farmaco antiinflamatorio no esteroidal
SE9900961D0 (sv) Novel compounds
RU2002121646A (ru) 1,3-дизамещенные пирролидины в качестве антагонистов альфа-2-адренорецепторов
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
AU2007265515A1 (en) Combinations comprising 5HT6 modulators and cholinesterase inhibitors
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
RU2007106552A (ru) Конденсированные пиримидоны, пригодные для лечения и предотвращения злокачественного новообразования
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
JP2005533119A5 (cg-RX-API-DMAC7.html)
JP2005539062A5 (cg-RX-API-DMAC7.html)
JP2003516994A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20080117